`
`Page 1 of 2
`
`News
`Select
`
`
`Mylan Enhances Partnership with Biocon through
`Strategic Collaboration for Insulin Products
`
`
`PR Newswire
`PITTSBURGH
`
`Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
`PR Newswire
`
`PITTSBURGH, Feb. 13, 2013
`
`PITTSBURGH, Feb. 13, 2013 /PRNewswire/ -- Mylan (Nasdaq: MYL) today announced that it has
`entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the
`development and commercialization of generic versions of three insulin analog products.
`
`Mylan CEO Heather Bresch commented, "This collaboration builds off of our existing successful
`partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog
`products. This collaboration further expands and diversifies our pipeline of complex, difficult-to-
`manufacture products with strong future growth potential. Importantly, we believe we have the
`opportunity to be one of the first generic entrants in developed markets into the rapidly growing
`diabetes area, helping to address unmet needs and reduce the economic burden to those battling the
`disease and to the global healthcare system."
`
`Mylan President Rajiv Malik added, "Biocon has served as a trusted development partner for the past
`three years, and we are very excited about this expanded relationship. Our thorough review of the
`development work completed by Biocon to date on these products gives us great confidence in the
`company's capabilities in this area and in the quality and value of this program. Our confidence in the
`potential of this program is supported by our proven ability to drive value from our partnership with
`Biocon and we believe Mylan is uniquely positioned to work with Biocon to bring these products to
`market."
`
`Biocon's Chairman & Managing Director, Kiran Mazumdar-Shaw said, "Mylan is a natural preferred
`partner for our portfolio of generic insulin analogs and this collaboration only further strengthens our
`existing successful partnership. We are excited to team up with Mylan to be able to cost effectively
`address the disease and economic burden that diabetes poses to global health. We are confident that
`together we can build a strong global presence in generic insulin analogs and provide access to
`affordable therapy options to physicians, healthcare providers and diabetes patients worldwide."
`
`Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon's
`Glargine (the generic version of Sanofi's Lantus®), Lispro (the generic version of Eli Lilly and
`Company's Humalog®) and Aspart (the generic version of Novo Nordisk's NovoLog®). Mylan and
`Biocon will share development, capital and certain other costs to bring the products to market. Mylan
`will have exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the European
`Union and the European Free Trade Association countries through a profit-share arrangement with
`
`http://newsroom.mylan.com/press-releases?item=122834
`
`12/27/2018
`
`Sanofi Exhibit 2001.001
`Mylan v. Sanofi
`IPR2018-01675
`
`
`
`Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products - Feb 13, 2...
`Biocon. Mylan will have co-exclusive commercialization rights with Biocon in certain other markets
`around the world. All other transaction terms remain confidential.
`
`Page 2 of 2
`
`According to public filings, reported worldwide net sales of Lantus, Humalog and NovoLog for 2012
`were approximately $11.5 billion.
`
`This press release includes statements that constitute "forward-looking statements," including with
`regard to the collaboration and commercialization of the products and the company's future
`opportunities. These statements are made pursuant to the safe harbor provisions of the Private
`Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and
`uncertainties, actual future results may differ materially from those expressed or implied by such
`forward-looking statements. Factors that could cause or contribute to such differences include, but are
`not limited to: the content and timing of decisions by regulatory authorities related to the development
`and commercialization of the products; difficulties or delays in manufacturing; demand for and market
`acceptance for the products; the impact of competitive products and pricing; and the other risks
`detailed in the company's periodic filings with the Securities and Exchange Commission. The company
`undertakes no obligation to update these statements for revisions or changes after the date of this
`release.
`About Mylan
`Mylan is a global pharmaceutical company committed to setting new standards in health care. Working
`together around the world to provide 7 billion people access to high quality medicine, we innovate to
`satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy
`and impact the future through passionate global leadership. We offer a growing portfolio of more than
`1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of
`antiretroviral therapies, upon which more than one-third of HIV/AIDS patients in developing countries
`depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and
`currently market products in approximately 150 countries and territories. Our workforce of more than
`18,000 people is dedicated to improving the customer experience and increasing pharmaceutical
`access to consumers around the world. But don't take our word for it. See for yourself. See inside.
`mylan.com
`About Biocon Limited
`Established in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is
`India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-
`Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on
`biopharmaceuticals and research services. Biocon's value chain traverses the entire length of
`discovery, development and commercialization of novel therapeutics. Biocon delivers affordable
`solutions to partners and customers in over 75 countries across the globe. Biocon's robust product
`offering includes the world's first Pichia-based recombinant human Insulin, INSUGEN®, Glargine,
`BASALOG® and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™ for head
`and neck cancer. www.biocon.com
`
`SOURCE Mylan Inc.
`
`http://newsroom.mylan.com/press-releases?item=122834
`
`12/27/2018
`
`Sanofi Exhibit 2001.002
`Mylan v. Sanofi
`IPR2018-01675
`
`